

DAFTAR PUSTAKA

1. Viprakasit V, Origa R. Genetic basis, pathophysiology and diagnosis [Chapter 1]. Dalam: Cappellini MD, Cohen A, Porter J, penyunting. Guidelines for the management of transfusion dependent thalassaemia (TDT) edisi ke 3 3rd edition. USA: Thalassaemia International Federation; 2014. h. 14-25
2. Debaun MR, Frei O, Jones MJ, Vichinsky EP. Thalassaemia syndromes. Dalam: Kliegman RM, Stanton BF, St Geme III JW, Schor NF, Behrman RE. Nelson Textbook of Pediatrics edisi ke-20. Philadelphia: Elsevier; 2016. h. 2349-52.
3. Kelly N. Thalassaemia. Pediatrics in Review. 2012; 33 (9): h. 434-5.
4. Flint J, Harding RM, Boyce AJ, Clegg JB. The population genetics of the hemoglobinopathies. Bailliere's Clinical Hematology. 1998; 11: h. 1-50.
5. Pencegahan thalassaemia (hasil kajian HTA tahun 2009). Jakarta: Dirjen Bina Pelayanan Medik Kementerian Kesehatan Republik Indonesia. 2010.
6. Lanni, F. Heterogenitas molekular gena globin- β di Indonesia: kaitannya dengan pola penyebaran thalassaemia- β serta afinitas genetik antar populasi di Indonesia. Disertasi, tidak diterbitkan. Yogyakarta: UGM; 2002.
7. Hidayat I. Thalassaemia dan permasalahannya di Indonesia. Sari pediatric. 2003; 5 (1): h. 2-3
8. Weatherall DJ. Disorders of globulin synthesis: the thalassaemias. Dalam: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, penyunting. Williams Hematology, edisi ke 7. New York: McGraw-Hill Book Company; 2006. h. 633-67.
9. Najafipour F. Evaluation of endocrine disorders in patients with thalassaemia major. Int J Endocrinol Metab. 2008; 2: h. 104-13
10. Arrigo T, Crisafulli G, Meo A, Sturiale M, Lombardo F, Miceli M, Cucinotta D, De Luca F. Glucose tolerance, insulin secretion and peripheral sensitivity in thalassaemia major. J Pediatr Endocrinol Metab. 1998; 11: h.

863–6

11. Chern JPS, Lin K-S, Lin K-H, Chen J-D, Lu M-Y, Fu C-C, Lin DT. Abnormal glucose tolerance in transfusion dependent β - thalassemia patients. *Diab Care*. 2001; 24: h. 850-4
12. De Sanctis V, Zurlo MG, Senesi E, Boffa C, Cavallo L, Di Gregorio F. Insulin dependent diabetes in thalassemia. *Arch Dis Child*. 1988; 63: h. 58–62
13. Flynn DM, Fairney A, Jackson D, Clayton BE. Hormonal changes in thalassemia major. *Arch Dis Child*. 1976; 51: h. 828–36
14. Gulati R, Bhatia V, Agarwal SS. Early onset of endocrine abnormalities in β -thalassemia major in a developing country. *J Pediatr Endocrinol Metab*. 2000; 13: h. 651–6
15. McIntosh N. Endocrinopathy in thalassemia major. *Arch Dis Child*. 1976; 51: h. 195–201
16. Sactis VD, Skordis N, Solirhan AT, Endocrine disease [Chapter 8]. Dalam: Cappellini MD, Cohen A, Porter J dkk, penyunting. Guidelines for the management of transfusion dependent thalassaemia (TDT) edisi ke 3. USA: Thalassemia International Federation; 2014. h. 151-4
17. Lanzkowsky P. Manual of pediatric hematology and oncology edisi ke 5. UK: Elsevier. 2011. h. 234-45
18. Viprakasit V, Porter J. Iron overload and chelation [Chapter 3]. Dalam: Cappellini MD, Cohen A, Porter J, penyunting. Guidelines for the management of transfusion dependent thalassaemia (TDT) edisi ke 3. USA: Thalassemia International Federation; 2014. h. 42-74
19. Sanctis VD, Soliman AT, Elsedfy H, Al Yaarubi S, Skordis N, Khater D dkk. The ICET-A recommendation for the diagnosis and management of disturbance of glucose homeostasis in thalassemia major patients. *Mediterr J Hematol Infect Dis*. 2016; 8 (1): h. 1-14
20. Angelucci E, Giovagnoni A, Valeri G. Limitations of magnetic resonance imaging in measurement of hepatic iron. *Blood*. 1997; 90: h. 4736-42.
21. Jensen PD, Jensen FT, Christensen T. Evaluation of myocardial iron by

- magnetic resonance imaging during iron chelation therapy with deferoxamine: indication of close relation between myocardial iron content and chelatable iron pool. *Blood*. 2003; 101: h. 4632-9.
22. Noetzli LJ, Carson SM, Nord AS. Longitudinal analysis of heart and liver iron in thalassemia major. *Blood*. 2008; 112: h. 2973-8
23. Anderson LJ, Westwood MA, Holden S. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous deferoxamine: a prospective study using T2* cardiovascular magnetic resonance. *Br J Haematol*. 2004; 127: h. 348-55
24. MacLaren D, Morton J. *Biochemistry for sports and exercise metabolism*. UK: John Wiley & Son; 2012. h. 91
25. Hein M, Arena S. *Foundation of College Chemistry edisi ke 13*. USA: Wiley and Sons; 2011. h. 510
26. Hall JE. *Guyton and hall textbook of medical physiology edisi ke 12*. Philadelphia: Elsevier; 2011. h. 1501-4, 1724-39.
27. Tortora GJ, Derrickson B. *Principles of anatomy & physiology edisi ke 14*. USA: John Wiley & Sons. 2014. h. 642-6, 943.
28. Zilmans CWRW, Van Kempen AAMW, Serlie MJ, Sauerwein HP. Glucose metabolism in children: influence of age, fasting and infectious disease. *Metabolism Clinical and Experimental*. 2009; 58: h. 1356-65
29. Estridge BH, Reynolds AP, Waters NJ. *Basic Medical laboratory Technique edisi ke empat*. USA: Thomson Learning; 2000. h. 403
30. Batubara JRL, APP Tridjaja B, Pulungan AB. *Buku ajar endokrinologi anak, edisi ke 1*. Jakarta: IDAI. 2015. h. 125
31. Svoren, BM. Jospe N. Diabetes mellitus. Dalam: Kliegman RM, Stanton BF, St Geme III JW, Schor NF, Behrman RE. *Nelson Textbook of Pediatric edisi ke-20*. Philadelphia: Elsevier; 2016. h. 2760-90
32. Pulungan, A. Increasing incidence of DM type 1 in Indonesia. *Int J Pediatr Endocrinol*. 2013; (Suppl 1): h. O12

33. Julia M, Utari A, Moelyo AG, Nurrochmah. Konsensus nasional pengelolaan DM tipe 2. Jakarta: Ikatan Dokter Anak Indonesia UKK Endokrinologi. 2015.
34. Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, Kaufman FR, Linder B, Marcovina S, McGuigan P, dkk. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. *J Clin Endocrinol Metab.* 2011; 96: h. 159–67
35. De P, Mistry R, Wright C, Pachan S, Burbridge W, Gangopadhyay K dkk. A review of endocrine disorder in thalassemia. *Open Journal of Endocrine and Metabolic Diseases.* 2014; 4: h. 25-34
36. Al-akhras A, Badr M, El-safy U, Kohne E, Hassan, Abdelrahman H, Mourad M, Brintrup J, Zakaria M. Impact of genotype on endocrine complication in β -thalassemia patients. *Biomedical reports.* 2016; 4: h. 728-36
37. MR Gamberini, Fortini M, De Sanctis V, Gilli G, Testa MR. Diabetes mellitus and impaired glucose tolerance in thalassemia major: incidence, prevalence, risk factors and survival in patients followed in the ferrara centre. *Pediatric Endocrinology Reviews.* 2004; 2 (2): h. 285-91
38. Metwalley KA, El-saeid ARAH, Glucose homeostasis in egyptian children and adolescent with β -thalassemia mayor: relationship to oxidative stress. *Indian Journal of Endocrinology and Metabolism.* 2014; 18 (3): h. 333-9
39. Altincik A, Akin M. Prevalence of endocrinopathies in Turkish children with β -thalassemia mayor: a single center study. *J Pediatric hematomol oncol.* 2016; 38: h. 389-93
40. Liang Y, Bajoria R, Jiang Y, Su H, Pan H, Xia N, Chatterjee R, Lai Y. Prevalence of diabetes mellitus in Chinese children with thalassemia major. *Tropical medicine and international health.* 2017; 22 (6): h 716-24
41. Toumba M, Sergis S, Kanaris C, Skordis N. Endocrine complication in patients with thalassemia major. *Pediatric Endocrinol Rev.* 2007; 5 (2): h 642-8

commit to user

42. Sharma S, Dutt N, Sidhu M, Digra S, Meenia R. Prevalence of hypothyroidism, diabetes mellitus and delayed puberty in patient of thalassemia major in a tertiary care center of Jammu province, Jammu kashir, India. *Int J Adv Med* 2017; 4 (3): h. 673-7
43. Wirawan R, Setiawan S, Kusnandar S, Munthe BG. Diabetes mellitus in β -thalassemia major patients. *Med J Indones.* 2003; 12 (2): 87-93
44. Noetzli LJ, Mittelman SD, Watanabe RM. Pancreatic iron and glucose dysregulation in thalassemia major. *Am J Hematol.* 2012; 87: h. 155-60.
45. Soliman AT, Yasin M, El-awwa A, Sactis VD. Detection of glycemic abnormalities in adolescent with beta thalassemia using continuous glucose monitoring and oral glucose tolerance in adolescents and young adult with β -thalassemia major: pilot study. *Indian Journal of Endocrinology and Metabolism.* 2013;17 (3); h. 490-5
46. De Sanctis V, Soliman A, Yassin M. Iron overload and glucose metabolism in subjects with β -thalassaemia major: An Overview. *Curr Diabetes Rev.* 2013; 9: h. 332-41.
47. Angelopoulos NG, Zervas A, Livadas S. Reduced insulin secretion in normoglycaemic patients with beta-thalassaemia major. *Diabet Med.* 2006; 23: h. 1327-31.
48. Meyer C, Pimenta W, Woerle HJ. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. *Diabetes Care.* 2006; 29: h. 1909-14.
49. Sanctis VD, Soliman AT, Elsedfy H, Alessia P, Kattamis C, Kholy ME, Yassin M. Diabetes and glucose metabolism in thalassemia major: An Update. *Expert Review of Hematology.* 2015: h. 1-17
50. Monge L, Pinach S, Caramellino L, dkk. The possible role of autoimmunity in the pathogenesis of diabetes in B-thalassemia major. *Diabetes Metab.* 2001; 27(2 Pt 1): h. 149-54.
51. Rimondi F, Banin P, Gamberini MR, De Sanctis V. The continuous glucose monitoring system (CGMS) in patients with beta(thalassemia major and

- impaired glucose homeostasis: Preliminary results. *Pediatr Endocrinol Rev* 2008; 6: h. 190(2).
52. Telen MJ, Kaufman RE. The mature erythrocyte. Dalam: Greer JP, Forester J, penyunting. *Wintrobe's clinical hematology Edisi ke 11*, Philadelphia: Lippincot Williams and Wilkins. 2004. h. 230.
53. Tran H, Silva D, Petrovsky N. Case study: potential pitfalls of using hemoglobin A1c as the sole measure of glycemic control. *Clin Diabetes*. 2004; 22: h.141–3.
54. Goldstein DE, Little RR, Lorenz RA, Malone JJ, Nathan D, Peterson CM. Tests of glycemia in diabetes. *Diabetes Care* 1995. 18(6): h. 896–909.
55. Illery P, Hue G, Bordas-Fonfrede M, Chapelle JP, Drouin P, Levy-Marchal C, Perier C, Selam JL, Slama G, Thivolet C, Vialettes B: Hemoglobin A1C determination and hemoglobinopathies: problems and strategies. *Ann Biol Clin (Paris)*. 2002; 58: h. 425 –9.
56. Choudhary A, Giardina P, Antal Z. Unreliable oral glucose tolerance test and HbA1C in Beta Thalassaemia Major-A case for continuous glucose monitoring?. *Br J Haematol*. 2013; 162: h. 132–5
57. Kosecki SM, Rodgers PT, Adams MB. Glycemic monitoring in diabetics with sickle cell plus β -thalassemia hemoglobinopathy. *Ann Pharmacother*. 2005; 39: h. 1557-60.
58. Kattamis C, Delaporta P, Dracopoulou M. Credibility of HbA1c in diagnosis and management of disturbances of glucose and diabetes in tranfused patients with thalassemia. *Riv Ital Med Adolesc*. 2014; 12: h. 65-71.
59. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. *Diabetes Care*. 1995;1: h. 440-7.
60. Welsh KJ, Kirkman MS, Sacks DB. Role of glycalated proteins in the diagnosis and management of diabetes: research gaps and future directions. *Diabetes care*. 2016; 39: h. 1299-306.

61. Araki T, Ishikawa Y, Okazaki H. Japanese Red Cross GA Research Group. Introduction of glycated albumin measurement for all blood donors and the prevalence of a high glycated albumin level in Japan. *J Diabetes Investig* 2012;3: h. 492–7
62. Farmaki K, Angelopoulos N, Anagnostopoulos G. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta thalassaemia major. *Br J Haematol*. 2006; 134: h. 438-44.
63. Farmaki K, Tzoumari I, Pappa C. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. *Br J Haematol*. 2010; 148: h. 466–75
64. Dozio E, Gaetano ND, Findeisen P, Romanelli MMC. Glycated albumin: from biochemistry and laboratory medicine to clinical practice. *Endocrine*. 2016: h. 1-6
65. Yazdanpanaj S, Rabiee M, Tahriri M, Abdolrahim M, Rajab A, Jazayeri HE, Tayebi L. Evaluation of glycalated albumin (GA) and GA/HbA1c ratio for diagnostic diabetes and glycemic control: a comprehensive review. *Clinical Reviews in Clinical Laboratory Sciences*. 2017; 54 (4): h. 219-32
66. Freitas PAC, Ehlert LR, Camargo JL. Glycalated albumin: a potential biomarker in diabetes. *Arch Endocrinol Metab*. 2017; 61(3); h. 296-304
67. Leaflet GA-L reagent. Tokyo: ASAHI KASEI PHARMA CORPORATION.
68. Koga M. Glycated albumin, clinical usefulness. *Clinica Chimica Acta*. 2014; 433: h. 96-104
69. Selvin E, Rawlings AM, Lutsey P, Maruthur N, Pankow JS, Steffes M, Coresh J. Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death. *Circulation*. 2015, 132 (4): h. 269-77
70. Paroni R, Ceriotti F, Galanello R, Leoni BG, Panico A, Scurati E dkk. Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin. *Clinical Biochemistry*. 2007; 40: h. 1398-405
71. Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T. Diabetes:

- effect of anemia and erythropoietin injection. *J Am Soc Nephrol.* 2007; 18: h. 896-903
72. Takahashi S, Uchino H, Shimizu T, Kanazawa A, Tamura Y, Sakai K dkk. Comparison of glycated albumin (GA) and glycaten hemoglobin (HbA1c) in type 2 Diabetic patientsL usefulness of GA for evaluation of short-term changes in glycemic control.*Endocrine Journal.* 2007; 54: h. 139-44
73. Yoshiuchi K, Mashuhisa M, Katakami M, Nakatani Y, Sakamoto K, Matsuoka T dkk. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. *Endocrine Journal.* 2008; 55 (3): h. 503-7
74. Peacock TP, Shihabi ZK, Bleyer AJ, Dolbare EL, Byers JR, Knovich MA. Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. *Kidney International.* 2008; 73: h. 1062-8
75. Koga M, Murai J, Saito H, Matsumoto S, Kasayama S. Effect of thyroid hormone on serum glycalated albumin levels: study on non0diabetic subjects, *Diabetes Research and Clinical Practice.* 2009; 84: h. 163-7
76. Beck R, Steffes M, Xing D, Ruedy K, Mauras N, Wilson DM, Kollman C. The interrelationship of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitol, and continuous glucose monitoring. *Pediatric Diabetes.* 2011; 12: h. 690-5.
77. N. Furusyo, T. Koga, M. Ai, S. Otokozaawa, T. Kohzuma, H. Ikezaki, E.J. Schaefer, J. Hayashi, Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Okinawa Population Study (KOPS). *Diabetologia.* 2011; 54(12): h. 3028–36
78. Hiramatsu Y, Shimizu I, Omori Y, Nakabayashi M. Determination of reference intervals of glycated albumin and hemoglobin A1c in healthy pregnant Japanese women and analysis of their time courses and influencing factors during pregnancy. *Endocrine Journal.* 2012; 59 (2): h. 145-51
79. Suzuki S, Koga M, Noriyasu N, Furuya A, Matsuo K dkk. Age-adjusted

- glycated albumin: a more robust parameter to establish glycaemic control in neonatal diabetes mellitus. *Annals of Clinical Biochemistry*. 2014; 51 (5): h. 602-5
80. Chan CL, Pyle L, Kelsey M, Newnes L, Zeitler PS, Nadeau KJ, Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemia- 1,5-anhydroglucitol, fructosamine and glycated albumin. *Pediatric Diabetes*. 2015: h. 1-6
81. Selvin E, Rawlings AM, Lutsey P, Maruthur N, Pankow JS, Steffes M, Coresh J. fructosamine and glycated albumin and the risk of cardiovascular outcomes and death. *Circulation*. 2015; 132 (4): h. 269-77
82. Wu WC, Ma WY, Wei JN, Yu TY, Lin MS, Shih SR, et al. Serum glycated albumin to guide the diagnosis of diabetes mellitus. *Plos one*. 2016; 11 (1): h. e0146780
83. Sugawara D, Kawano A, Kohei N, Hiroki S, Ko I. Glycated albumin level during late pregnancy as a predictive factor for neonatal outcomes of women with diabetes. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2017: h. 1-30
84. Devi TT, Dalimoenthe NZ, Tristina N, Lismayanti L. Kadar *glycated* albumin pada penderita *transfusion dependent thalassemia* di RSUP dr. Hasan Sadikin Bandung. *J Indon Med Assoc*. 2017; 67 (11): h. 544-9.
85. Gul A, Sharif N, Zahoorullah, Ahmed S. Diabetes: comparison of HbA1c and serum glycated albumin levels as monitoring tool. *Professional Med J*. 2018; 25 (1): h. 109-14
86. Bellia C, Zaninotto M, Cosma C, Agnello L, Bivona G, Marinova M. Clinical usefulness of glycated albumin in the diagnosis of diabetes: result from an Italian study. *Clinical Biochemistry*. 2018; 54: h. 68-72
87. Dahlan SM. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan edisi ke 3. Jakarta: Salemba Medika; 2010. h. 85-90
88. Kosaryan M, Rahimi M, Darvishi-Khezr H, Gholizadeh N, Akbarzadeh A, Aliasgharian A. Correlation of pancreatic iron overload measured by T2*-

- weighted magnetic resonance imaging in diabetic patients with thalassemia mayor. *Hemoglobin*. 2017; h. 1-5
89. The expert comitte on the diagnosis and classification of diabetes mellitus. Report of the expert comitte on the diagnosis and classification of diabetes mellitus. *Diabetes Care*. 1997; 20 (7): h. 1183-97
90. Perkumpulan Endokrinologi Indonesia. Konsensus pengelolaan dan pencegahan diabetes mellitus tipe 2 di Indonesia. Indonesia: PERKENI. 2011. h. 7-8
91. Faizi M, Rini EA, Yati NP, Artati RA, Purwana INA, Arto KS. Prosedur Diagnostik. Dalam: Batubara JRL, APP Tridjaja B, Pulungan AB. Buku ajar endokrinologi anak, edisi 2. Jakarta: IDAI, 2018. h. 553-4
92. Steffes, M. Laboratory procedure manual: fasting glucose. USA: NHANES. 2007.
93. American Psychological Association. Guidelines for Psychological Practice with Lesbian, Gay, and Bisexual Clients. *American Psychologist*. 2012; 67 (1): h. 10-42
94. Tjahjono HA, Aditiawati, Pulungan AB, Marzuki ANS, Rini EA, Himawan IW, Batubara JRL. Panduan praktik klinis ikatan dokter anak Indonesia: perawakan pendek pada anak dan remaja di Indonesia. Jakarta: UKK Endokrinologi IDAI. 2017.
95. Sjarif DR . Prinsip asuhan nutrisi pada anak. Dalam: Sjarif DR, Lestari ED, Mexitalia M, Nasar SS. Buku ajar nutrisi dan penyakit metabolic edisi ke 2. Jakarta: IDAI. 2014. h. 40-41
96. Billet HH. Hemoglobin and hematocrit. Dalam: Walker HK, Hall WD, Hurst JW penyunting. *Clinical methods: the history, physical, and laboratory examination* edisi ke 3. USA: Butterworths; 1990.
97. Mohseni F, Mohajeri-tehrani MR, Larijani B, Hamidi Z. Relation between BMD and biochemical, transfusion and endocrinological parameters in pediatric thalassemic patients. *Arch Osteoporos*. 2014; 9 (174): h. 1-6
98. Elalfy MS, Ebeid FSE, Yasmin EG, Islam E, Amna K. Metabolic profile & body composition in Egyptian children with transfusion-dependent

- Egyptian B-thalassemia. *Blood*. 2018; 132 (1): h. 4903
99. Moiz B, Habib A, Sawani S, Raheem A, Hasan B, Gangwani M. Anthropometric measurement in children having transfusion-dependent beta thalassemia. *Hematology*. 2018; 4: h. 248-52
100. Fadlyana E, Ma'ani F, Elizabeth M, Reniarti L. Correlation between serum ferritin level and growth disorders in children with thalassemia. *American Journal of Clinical Medical Research*. 2017; 5 (3): h. 31-5
101. Alfalah C, Wisnumurti DA, Windiastuti E, Sjakti HA, Putro D, Wulandari HF et al. Pengaruh kadar hemoglobin pretransfusi dan ferritin serum dengan pertumbuhan fisik pasien thalassemia β mayor. *Sari Pediatri*. 2018; 19 (6): h. 349-55
102. Hendaro A, Sari TT, Rahmartani LD, Widyasari A, Iskandar SD. Glucose and lipid profiles in adolescent with thalassemia major and its association with iron overload in specific organ. *The Indonesian Biomedical Journal*. 2019; 11 (2): h. 188-93.
103. Bas M, Gumruk F, Gonc N, Cetin M, Tuncer M, Hazurolan T et al. Biochemical marker of glucose metabolism may be used to estimate the degree and progression of iron overload in the liver and pancreas of patient with β -thalassemia major. *Ann Hematol*. 2011. h. 1-6
104. Aekplakorn W, Tantayotai V, Numsangkul S, Sripho W, Tatsto N, Burapasiriwat T et al. Detecting prediabetes dan diabetes aggrement between fasting plasma glucose and oral glucose tolerance test in Thai adults. *Hindawi*. 2015: h. 1-6
105. Kim DL, Kim SD, Song KH. Is an oral glucose tolerance test still valid for diagnosing diabetes mellitus?. *Diabetes Metab J*. 2016; 40 (2): h. 118-28
106. Abdul-Ghani M, DeFronzo RA, Jayyousi A. Prediabetes and risk of diabetes and associated complications: impaired fasting glucose versus impaired glucose tolerance: does it matter?. *Curr Opin Clin Nutr Metab Care*. 2016; 19: h. 394-9
107. Chume FC, Kielling MH, Camargo JL. Glycated albumin as diagnostic tool in diabetes: an alternative or additional test?. *Plos one*. 2019; 14 (2): h.

e0227065



commit to user

